Home » Stocks » EYPT

EyePoint Pharmaceuticals, Inc. (EYPT)

Stock Price: $8.17 USD -0.08 (-0.91%)
Updated Jul 26, 2021 9:36 AM EDT - Market open
Market Cap 236.83M
Revenue (ttm) 34.27M
Net Income (ttm) -44.50M
Shares Out 28.74M
EPS (ttm) -2.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $8.17
Previous Close $8.24
Change ($) -0.08
Change (%) -0.91%
Day's Open 8.28
Day's Range 8.17 - 8.51
Day's Volume 7,511
52-Week Range 3.51 - 15.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

6 days ago - GlobeNewsWire

WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

3 weeks ago - GlobeNewsWire

WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

4 weeks ago - GlobeNewsWire

WATERTOWN, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the li...

2 months ago - GlobeNewsWire

WATERTOWN, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the li...

2 months ago - GlobeNewsWire

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 5.66% and -11.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

EYP-1901 DAVIO study for the potential treatment of wet AMD dosed first patient in January; study remains on track for initial data in Q4 2021

2 months ago - GlobeNewsWire

On Wednesday, May 05, EyePoint Pharmaceuticals (NASDAQ:EYPT) will release its latest earnings report. Decipher the announcement with Benzinga's help.

2 months ago - Benzinga

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

WATERTOWN, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the ...

2 months ago - GlobeNewsWire

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -324.44% and -70.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the ...

4 months ago - Zacks Investment Research

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

5 months ago - GlobeNewsWire

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

5 months ago - GlobeNewsWire

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Stamps.com Inc. (STMP), Ribbon Communications Inc. (RBBN), American Software, Inc. (AMSWA) and E...

Other stocks mentioned: AMSWA, RBBN, STMP
5 months ago - Zacks Investment Research

WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

5 months ago - GlobeNewsWire

WATERTOWN, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

5 months ago - GlobeNewsWire

WATERTOWN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

5 months ago - GlobeNewsWire

- IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal  anti-VEGF treatment targeting wet age-related macular degeneration -

6 months ago - GlobeNewsWire

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...

Other stocks mentioned: ARGX, GILD, GRCL, INO, LLY, PRTK, ZLAB
6 months ago - Seeking Alpha

WATERTOWN, Mass., Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...

6 months ago - GlobeNewsWire

WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to help im...

7 months ago - GlobeNewsWire

WATERTOWN, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...

7 months ago - GlobeNewsWire

- No unexpected safety findings during the course of the study -

7 months ago - GlobeNewsWire

WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...

8 months ago - GlobeNewsWire

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...

8 months ago - GlobeNewsWire

EyePoint Pharmaceuticals, Inc.'s (EYPT) CEO Nancy Lurker on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -200.00% and 0.22%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...

8 months ago - Zacks Investment Research

EyePoint Pharmaceuticals (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, wi...

8 months ago - GlobeNewsWire

WATERTOWN, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...

9 months ago - GlobeNewsWire

- Q 3 20 20 net product revenues are estimated to be between $ 5.5 - $ 5.9 million, as healthcare facilities began reopening from COVID-19 closures -

9 months ago - GlobeNewsWire

WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

10 months ago - GlobeNewsWire

WATERTOWN, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

11 months ago - GlobeNewsWire

EyePoint Pharmaceuticals (EYPT) news from yesterday concerning a massive deal has EYPT stock continuing to climb higher on Friday. The post EyePoint Pharmaceuticals News: Why EYPT Stock Is Soaring 21% T...

11 months ago - InvestorPlace

WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

11 months ago - GlobeNewsWire

EyePoint Pharmaceuticals, Inc.'s (EYPT) CEO Nancy Lurker on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 9.09% and 46.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) moved lower by 2.5% in pre-market trading after the company reported Q4 results.

11 months ago - Benzinga

- Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic -

11 months ago - GlobeNewsWire

- Collaboration to bring DEXYCU to ImprimisRx’s established customer base of ophthalmologists, hospitals, and ambulatory surgical centers - - Collaboration to bring DEXYCU to ImprimisRx’s established cu...

11 months ago - GlobeNewsWire

WATERTOWN, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

11 months ago - GlobeNewsWire

WATERTOWN, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

11 months ago - GlobeNewsWire

- World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline -

1 year ago - GlobeNewsWire

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself.

Other stocks mentioned: BKYI, COCP, EYES, REPH
1 year ago - Forbes

If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.

Other stocks mentioned: AGEN, ATOM, AXLA, MGEN
1 year ago - Forbes

EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been this year.

Other stocks mentioned: BAND, COF, GHSI, HTBX
1 year ago - Forbes

As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks to short to...

Other stocks mentioned: BBI, DGLY, HTBX, MNKD
1 year ago - Forbes

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About EYPT

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treat... [Read more...]

Industry
Biotechnology
IPO Date
Jan 27, 2005
Stock Exchange
NASDAQ
Ticker Symbol
EYPT
Full Company Profile

Financial Performance

In 2020, EYPT's revenue was $34.44 million, an increase of 69.10% compared to the previous year's $20.37 million. Losses were -$45.39 million, -20.07% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for EYPT stock is "Buy." The 12-month stock price forecast is 19.08, which is an increase of 133.68% from the latest price.

Price Target
$19.08
(133.68% upside)
Analyst Consensus: Buy